Table 6 ACR responses at 6–18 months in those who entered phase II (intention‐to‐treat).

	Combination (n = 56)	SASP (n = 55)	MTX (n = 54)	SASP OR (95% CI)	p Value*	MTX OR (95% CI)	p Value*
ACR 20 response	16 (29%)	10 (18%)	8 (15%)	1.25 (0.56 to 2.79)	0.68	2.01 (0.85 to 4.76)	0.14
ACR 50 response	6 (11%)	3 (6%)	4 (7%)	1.43 (0.43 to 4.81)	0.76	1.79 (0.49 to 6.49)	0.53
ACR 70 response	2 (4%)	1 (2%)	1 (2%)	1.50 (0.24 to 9.34)	1.00	3.00 (0.30 to 29.78)	0.62

ACR, American College of Rheumatology; MTX, methotrexate; SASP, sulfasalazine.

The ORs are found with the combination group as the reference level.

*Fisher's exact text used.